EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

Tin May Aung, Chetta Ngamjarus, Tanakorn Proungvitaya, Charupong Saengboonmee, Siriporn Proungvitaya iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303337 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS ONE, 2024. Verfasst von Tin May Aung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thail…. Hauptthemen laut MEDLINE: Meningioma, Biomarkers, Tumor, Meningeal Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Fund of Khon Kaen University, Postdoctoral Researcher Fellowship Training Program from Khon Kaen University, Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Khon Kaen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. This study aims to evaluate the prognostic value of immunohistochemistry-based (IHC) biomarkers of meningioma patients. A systematic literature search was conducted up to November 2023 on PubMed, CENTRAL, CINAHL Plus, and Scopus databases. Two authors independently reviewed the identified relevant studies, extracted data, and assessed the risk of bias of the studies included. Meta-analyses were performed with the hazard ratio (HR) and 95% confidence interval (CI) of overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS). The risk of bias in the included studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool. A total of 100 studies with 16,745 patients were included in this review. As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II α (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). Although only in single studies, KPNA2, CDK6, Cox-2, MCM7 and PCNA are proposed as additional markers with high expression that are related with poor prognosis of meningioma patients. In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaBiomarkers, TumorMeningeal NeoplasmsHumansPrognosisDNA Topoisomerases, Type IIKi-67 AntigenTumor Suppressor Protein p53Vascular Endothelial Growth Factor AImmunohistochemistryPoly-ADP-Ribose Binding Proteins

Substanzen

Biomarkers, TumorDNA Topoisomerases, Type IIKi-67 AntigenTumor Suppressor Protein p53Vascular Endothelial Growth Factor APoly-ADP-Ribose Binding ProteinsTOP2A protein, human

Autor:innen und Institutionen

  • Centre of Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.

ORCID-Profile: Siriporn Proungvitaya

Förderung

  • Fundamental Fund of Khon Kaen University
  • Postdoctoral Researcher Fellowship Training Program from Khon Kaen University
  • Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Khon Kaen University

Zitieren

APA

Aung, T. M., Ngamjarus, C., Proungvitaya, T., Saengboonmee, C., & Proungvitaya, S. (2024). Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0303337

Vancouver

Aung TM, Ngamjarus C, Proungvitaya T, Saengboonmee C, Proungvitaya S. Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0303337

BibTeX
@article{Aung2024,
  author = {Aung, Tin May and Ngamjarus, Chetta and Proungvitaya, Tanakorn and Saengboonmee, Charupong and Proungvitaya, Siriporn},
  title = {Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303337}
}
Kostenlos starten →